tetano
Editor, Senior Moderator
J Clin Med
. 2022 Apr 8;11(8):2090.
doi: 10.3390/jcm11082090.
Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
Mineaki Kitamura[SUP] 1 2 [/SUP], Takahiro Takazono[SUP] 3 4 [/SUP], Kosei Yamaguchi[SUP] 1 2 [/SUP], Hideshi Tomura[SUP] 1 2 [/SUP], Kazuko Yamamoto[SUP] 3 4 [/SUP], Takashi Harada[SUP] 1 [/SUP], Satoshi Funakoshi[SUP] 1 [/SUP], Hiroshi Mukae[SUP] 4 5 [/SUP], Tomoya Nishino[SUP] 2 [/SUP]
Affiliations
Abstract
Patients undergoing hemodialysis are known to exhibit low humoral responses to vaccines against severe acute respiratory syndrome coronavirus 2. In this study, we aimed to elucidate the humoral response to the third dose of BNT162b2 (Pfizer) in patients undergoing hemodialysis. We included 279 patients undergoing hemodialysis (69 ± 11 years, 65% male, median dialysis vintage: 69 months) and 189 healthcare workers (45 ± 13 years, 30% male) who received the third dose of BNT162b2. Anti-spike immunoglobulin G (anti-S IgG) antibody levels were measured 3-4.5 months after the second dose and 3 weeks after the third dose and were compared. Despite a significant difference in anti-S IgG antibody levels after the second dose between the two groups (patients: median 215 U/mL and healthcare workers: median 589 U/mL; p < 0.001), no significant difference in anti-S IgG antibody levels after the third dose was observed (patients: median 19,000 U/mL, healthcare workers: median 21,000 U/mL). Except for dialysis vintage (ρ = 0.209, p < 0.001), no other factors correlated with anti-S IgG antibody levels after the third vaccine dose in patients undergoing hemodialysis. Therefore, a favorable response to the third dose of BNT162b2 was observed in patients undergoing hemodialysis, irrespective of their backgrounds.
Keywords: coronavirus disease 2019; hemodialysis; humoral response; immunogenicity; severe acute respiratory syndrome coronavirus 2; third dose; vaccination.
. 2022 Apr 8;11(8):2090.
doi: 10.3390/jcm11082090.
Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
Mineaki Kitamura[SUP] 1 2 [/SUP], Takahiro Takazono[SUP] 3 4 [/SUP], Kosei Yamaguchi[SUP] 1 2 [/SUP], Hideshi Tomura[SUP] 1 2 [/SUP], Kazuko Yamamoto[SUP] 3 4 [/SUP], Takashi Harada[SUP] 1 [/SUP], Satoshi Funakoshi[SUP] 1 [/SUP], Hiroshi Mukae[SUP] 4 5 [/SUP], Tomoya Nishino[SUP] 2 [/SUP]
Affiliations
- PMID: 35456182
- PMCID: PMC9024432
- DOI: 10.3390/jcm11082090
Abstract
Patients undergoing hemodialysis are known to exhibit low humoral responses to vaccines against severe acute respiratory syndrome coronavirus 2. In this study, we aimed to elucidate the humoral response to the third dose of BNT162b2 (Pfizer) in patients undergoing hemodialysis. We included 279 patients undergoing hemodialysis (69 ± 11 years, 65% male, median dialysis vintage: 69 months) and 189 healthcare workers (45 ± 13 years, 30% male) who received the third dose of BNT162b2. Anti-spike immunoglobulin G (anti-S IgG) antibody levels were measured 3-4.5 months after the second dose and 3 weeks after the third dose and were compared. Despite a significant difference in anti-S IgG antibody levels after the second dose between the two groups (patients: median 215 U/mL and healthcare workers: median 589 U/mL; p < 0.001), no significant difference in anti-S IgG antibody levels after the third dose was observed (patients: median 19,000 U/mL, healthcare workers: median 21,000 U/mL). Except for dialysis vintage (ρ = 0.209, p < 0.001), no other factors correlated with anti-S IgG antibody levels after the third vaccine dose in patients undergoing hemodialysis. Therefore, a favorable response to the third dose of BNT162b2 was observed in patients undergoing hemodialysis, irrespective of their backgrounds.
Keywords: coronavirus disease 2019; hemodialysis; humoral response; immunogenicity; severe acute respiratory syndrome coronavirus 2; third dose; vaccination.